Open access
Oct 2026
Upfront combination lipid-lowering therapy in statin-naive acute coronary syndrome patients with high admission LDL-C: real-world support for the 2025 ESC dyslipidaemias guidelines
The findings strongly support the 2025 ESC/EAS Guidelines update: in patients with LDL-PMF, adding ezetimibe to high-intensity statins at discharge significantly increases the likelihood of achieving the <55 mg/dL target compared to monotherapy.
A. M. Hernandez, J. M. Andreu Cayuelas, F. B. Santiago et al.
· European Heart Journal · 0 citations